Tracking myeloma tumor DNA in peripheral blood

Publication date: Available online 14 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Johannes M. Waldschmidt, Tushara Vijaykumar, Birgit Knoechel, Jens G. LohrAbstractOver the past years, the emergence of liquid biopsy technologies has dramatically expanded our ability to assess multiple myeloma without the need for invasive sampling. Interrogation of cell-free DNA from the peripheral blood recapitulates the mutational landscape at excellent concordance with matching bone marrow aspirates. It can quantify disease burden and identify previously undetected resistance mechanisms which may inform clinical management in real-time. The convenience of sample acquisition and storage provides strong procedural benefits over currently available testing. Further investigations will have to define the role of cell-free DNA as a diagnostic measure by determining clinically relevant tumor thresholds in comparison to existing routine parameters. This review presents an overview of currently available assays and discusses the clinical value, potential and limitations of cell-free DNA technologies for the assessment of this challenging disease.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research